Here are the worst biopharma CEOs of 2023; In Spain, a hospital brews its CAR-T therapy

Taking stock of the drug industry, from the lab to the medicine chest

December 19, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Hyacinth Empinado/STAT STAT+ | Here are the worst biopharma CEOs of 2023 Pfizer is this year's anti-Eli Lilly. If David Ricks is the best biopharma CEO of 2023, then Pfizer CEO Albert Bourla is the worst. By Adam Feuerstein STAT+ | In the U.S., scientists see barriers to the development of CAR-T cell therapies. In Spain, a hospital brews its own Under a special European policy, the CAR-T won regulatory approval and was reimbursed by the national health system. By Andrew Joseph STAT+ | Prime Medicine, Mukherjee's Myeloid Therapeutics clash over genome-editing deal The biotech companies have filed competing arbitration claims over an agreement they signed in March 2022. By Jason Mast and Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser